Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Sort by Popularity (sales)

Display 15 Products per page

Company Analysis: Roche

$3,000.00

PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Celgene

$3,000.00

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 8, 2018
Find out more
Trends: Hot Topic Catalyst

$750.00

The FDA Amendments Act (FDAAA) provided the FDA with new powers in relation to drug safety, including the authority to impose postmarketing requirements (PMRs) and Risk Evaluation and Mitigation Strategies (REMS) on drug manufacturers.
November 19, 2020
Find out more
Allergan

$3,000.00

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 10, 2018
Find out more
Company Analysis: United Therapeutics

$3,000.00

PharmaVitae explores United Therapeutics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

$3,000.00

This decade has seen the emergence of therapies harnessing the immune system to treat cancer.
October 1, 2018
Find out more
Company Analysis: Vertex

$3,000.00

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Under the Radar Takeover Targets

$3,000.00

Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.
July 20, 2018
Find out more
Acorda Company Analysis

$3,000.00

PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.
February 9, 2018
Find out more
JP Morgan Healthcare Conference Review

$3,000.00

The 2018 JP Morgan Healthcare Conference held in San Francisco over 8–11 January 2018 was light on big news and deals, but PharmaVitae picked up on key themes for some of the presenting companies in our coverage universe, which are all experiencing and/or pursuing a change of scene and pace in dealmaking activity.
January 18, 2018
Find out more
Company Analysis: Incyte

$3,000.00

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Pharma-Payer Partnerships in Emerging Markets

$2,995.00

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.
July 26, 2017
Find out more
Company Analysis: Novo Nordisk

$3,000.00

PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Novartis

$3,000.00

PharmaVitae explores Novartis’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Bristol-Myers Squibb

$3,000.00

PharmaVitae explores Bristol-Myers Squibb’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *